Evidence map›Paper›PMID 33838016›Full record

ArticleCancer medicine2021

miR-140-3p inhibits colorectal cancer progression and its liver metastasis by targeting BCL9 and BCL2.

Dingsheng Liu, Chunsheng Chen, Mingming Cui, Hong Zhang

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Exosomes in metastasis of colorectal cancers: Friends or foes?World journal of gastrointestinal oncology · 2023
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Dingsheng LiuDepartment of General Surgery, Shengjing Hospital of China Medical University, Shenyang, People's Republic of China.
Chunsheng ChenDepartment of General Surgery, Shengjing Hospital of China Medical University, Shenyang, People's Republic of China.
Mingming CuiDepartment of General Surgery, Shengjing Hospital of China Medical University, Shenyang, People's Republic of China.
Hong ZhangDepartment of General Surgery, Shengjing Hospital of China Medical University, Shenyang, People's Republic of China.ORCID 0000-0002-7811-8629
China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies have identified microRNAs (miRNAs) as a compelling novel class of biomarker in colorectal cancer (CRC) development and metastasis. Here, we demonstrated that the level of plasma exosomal miR-140-3p in CRC patients was lower than that in healthy controls. The decreased miR-140-3p level was also observed in CRC patients with liver metastasis. The expression of miR-140-3p in CRC tissues were significantly lower than that in matched normal tissues. Functionally, miR-140-3p overexpression suppressed proliferation, migration, invasion, and β-catenin nuclear translocation, as well as promoted apoptosis in LoVo cells, while inhibition of miR-140-3p reversed these cellular processes in HCT 116 cells. Notably, BCL9 and BCL2 were recognized as direct targets of miR-140-3p. BCL9 knockdown abrogated miR-140-3p inhibitor-induced effects on HCT 116 cells with decreased proliferation, migration, and invasion. BCL2 knockdown increased apoptosis of miR-140-3p inhibitor-transfected HCT 116 cells. In vivo experiments revealed that miR-140-3p overexpression inhibited tumor growth in LoVo xenograft model and diminished metastatic nodules in nude mice liver. Taken together, this work supports that miR-140-3p exerts as a tumor suppressor in CRC progression via targeting BCL9 and BCL2, and suggests miR-140-3p-BCL9/BCL2 axis may be applied in miRNA-based therapy and prognostication of CRC.

Indexed as

AnimalsApoptosisbeta CateninCell Line, TumorCell MovementCell ProliferationColorectal NeoplasmsDisease ProgressionGene Expression Regulation, NeoplasticHCT116 CellsHumansLiver NeoplasmsMaleMiceMice, Inbred BALB CMice, NudeBCL2 protein, humanBCL9 protein, humanbeta CateninMicroRNAsMirn140 microRNA, humanProto-Oncogene Proteins c-bcl-2Transcription FactorsBCL2BCL9colorectal cancermetastasismiR-140-3p

Identifiers

PMID33838016
PMCPMC8124101
OpenAlexW3146250412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.